ISSN: 1697-090X


Indice del volumen
Volume index

Comité Editorial
Editorial Board

Comité Científico
Scientific Committee

Normas para los autores
Instruction to Authors

Derechos de autor Copyright


    Rev Electron Biomed / Electron J Biomed 2019;3:2-5.



    Mario Arturo González Mariño, MD. PhD.
    Profesor Facultad de Medicina
    Universidad Nacional de Colombia
    Bogotá. Colombia

    Version en español

    Breast cancer is the most commonly malignant neoplasm diagnosed in women (2.1 million new cases in 2018) and the leading cause of cancer death worldwide (627,000 deaths). In many countries with high levels of the human development index, incidence rates have stabilized while mortality rates are declining1. These results are due in part to mammographic screening, but other variables also participate such as greater care with risk factors and an important development in treatments. In Spain, the adjusted mortality rate increased gradually until the beginning of the 1990s, since then, coinciding with the beginning of the screening programs, it has been decreasing considerably, going from a mortality rate of 17,8 / 100,000 in 1993, to 10.6 / 100,000 (age-standardized rates) in 20202. Contrary to this trend, in areas with a low level of development of screening and with limitations in health services there is an increase in incidence and mortality, reaching the current situation where more than half of the cases of breast cancer are diagnosed in low- and middle-income countries, and mortality rates have increased in the countries of Asia and Latin America1.

    In the preventive approach of women with average risk for breast cancer there are several strategies, some of which have to do with reducing modifiable risk factors and stimulating protective factors through changes in lifestyle3. However, even though these changes are useful in promoting health, they are factors that are not found in most breast cancers, so the greatest impact on the population is achieved with secondary prevention actions through the development of screening programs whose objective is to detect the disease at an early stage that allows effective treatments to improve the results of the disease, including the indicator of specific mortality from breast cancer4,5.

    Mammography is the most widely used screening modality for the detection of breast cancer due to its availability, defined quality control, support of prospective randomized studies6,7 and the experience of its population application as mentioned above. An independent review of 11 randomized controlled studies found a reduction in breast cancer mortality of approximately 20%8.

    It is considered that the biggest risk factor for breast cancer is being female followed by advancing age9. When evaluating meta-analyzes of randomized clinical trials that stratified by age, screening women younger than 50 years was consistently associated with a statistically significant reduction in breast cancer mortality of approximately 15%. Screening of women aged 50 years or older was associated with a slightly greater mortality reduction (14%-23%), mostly related to a greater reduction in women aged 60 to 69 years (31%-32%)7. In a randomized controlled trial involving 23 breast screening units in Great Britain, the effect of mammographic screening in the ages 40 to 49 years on breast cancer mortality was evaluated, finding a 25% reduction in mortality in breast cancer patients in the first ten years with annual mammogram10. This result, which supports a change in the age of initiation of screening, has generated a great debate about its results11,12.

    Breast cancer screening with mammography is currently the best strategy for the early population detection of breast cancer with age as a criterion to include women in the organized program, mainly due to the evidence that the screening scheme decreases breast cancer mortality in women aged 50 to 69 years9 (although this has had also a highly intense debate with important contradictors11) but it has limitations both in diagnostic performance and because of the possibility of obtaining harmful results, including the detection of clinically insignificant cancers that do not pose a threat to life (overdiagnosis)9. It is expected that in the future there will be better technology that overcomes these disadvantages as well as better risk classification of women who require the screening test and the need for additional tests or new methods for breast screening; options on which there is already a great deal of research activity.


      1.- Wild CP, Weiderpass E, Stewart BW, editors (2020). World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer.

      2.- Global Cancer Observatory. International Agency for Research on cancer. Disponible en: [consultado 27 de Diciembre 2020].

      3.- Thorat MA, Balasubramanian R. Breast cancer prevention in high-risk women. Best Practice & Research Clinical Obstetrics and Gynaecology 2020;65:18-31.

      4.- Niell BL, Freer PE, Weinfurtner RJ, Arleo EK, Drukteinis JS. Screening for Breast Cancer. Radiol Clin N Am 2017;55 :1145-1162.

      5.- Harkness EF, Astley SM, Evans DG. Risk-based breast cancer screening strategies in women. Best Practice & Research Clinical Obstetrics and Gynaecology 2020; 65: 3-17.

      6.- Saccarelli CR, Bitencourt AGV, Morris EA. Is It the Era for Personalized Screening? Radiol Clin North Am. 2021;59(1):129-138.

      7.- Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S, Davidson B, Mongtomery RC, et al. Benefits and Harms of Breast Cancer Screening: A Systematic Review. JAMA 2015; 314 (15) :1615-34.

      8.- Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer 2013; 108:2205-2240.

      9.- PDQ Screening and Prevention Editorial Board. Breast Cancer Screening (PDQ®). Breast Cancer Screening (PDQ): Health Professional Version. 2020 Aug 27. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-.PMID: 26389344 .

      10.- Duffy SW, Vulkan D, Cuckle H, Parmar D, Sheikh S, Smith RA, Evans A, et al. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial. Lancet Oncol. 2020;21(9):1165-1172.

      11.- Miller A. Final results of the UK Age trial on breast cancer screening age. Lancet Oncol. 2020 Sep;21(9):1125-1126.

      12.- Wise J. Breast cancer: study claiming that screening women in their 40s saves lives "found the opposite," say critics. BMJ. 2020 ;370:m3191.

    Dr. Mario Arturo González Mariño
    Profesor Facultad de Medicina
    Universidad Nacional de Colombia
    Bogotá. Colombia
    Email: marioar90 @